Last reviewed · How we verify

CSII+Vildagliptin — Competitive Intelligence Brief

CSII+Vildagliptin (CSII+Vildagliptin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor (combined with insulin therapy). Area: Diabetes.

marketed DPP-4 inhibitor (combined with insulin therapy) DPP-4 (dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

CSII+Vildagliptin (CSII+Vildagliptin) — The First Affiliated Hospital of Xiamen University. CSII (continuous subcutaneous insulin infusion) combined with vildagliptin, a DPP-4 inhibitor, delivers insulin continuously while enhancing endogenous insulin secretion by inhibiting dipeptidyl peptidase-4.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CSII+Vildagliptin TARGET CSII+Vildagliptin The First Affiliated Hospital of Xiamen University marketed DPP-4 inhibitor (combined with insulin therapy) DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor (combined with insulin therapy) class)

  1. The First Affiliated Hospital of Xiamen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CSII+Vildagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/csii-vildagliptin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: